Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Novel Therapies in Acute Lymphoblastic Leukemia

Novel Therapies in Acute Lymphoblastic Leukemia Purpose of Review Treatment options for patients with acute lymphoblastic leukemia (ALL) beyond standard chemotherapy have grown significantly in recent years. In this review, we highlight new targeted therapies in ALL, with an emphasis on immunotherapy. Recent Findings Major advances include antibody-based therapies, such as naked monoclonal antibodies, antibody-drug conju- gates and bispecific T cell engaging (BiTE) antibodies, as well as adoptive cellular therapies such as chimeric antigen receptor (CAR) Tcells. Apart from the above immunotherapeutic approaches, other targeted therapies are being employed in Philadelphia chromosome-positive (Ph+) ALL, Philadelphia-like (Ph-like) ALL, and T cell ALL. Summary These new treatment strategies are changing the treatment landscape of ALL and challenging the current standard of care. Clinical trials will hopefully help determine how to best incorporate these novel therapies into existing treatment algorithms. . . . . . Keywords Acute lymphoblastic leukemia ALL Adult Treatment Immunotherapy Relapsed/refractory I. Introduction Significant advances in our understanding of ALL patho- genesis in recent years have led to the development of prom- Acute lymphoblastic leukemia (ALL) is a heterogeneous ising treatment options beyond conventional chemotherapy. group of hematologic malignancies characterized by impaired Many of these therapies target specific subsets of ALL, capi- differentiation and proliferation http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Hematologic Malignancy Reports Springer Journals

Novel Therapies in Acute Lymphoblastic Leukemia

Download PDF
11 pages

Loading next page...
 
/lp/springer-journals/novel-therapies-in-acute-lymphoblastic-leukemia-VkN3OXUN60

References (90)

Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer Science+Business Media, LLC, part of Springer Nature
Subject
Medicine & Public Health; Hematology; Oncology; Geriatrics/Gerontology
ISSN
1558-8211
eISSN
1558-822X
DOI
10.1007/s11899-018-0457-7
Publisher site
See Article on Publisher Site

Abstract

Purpose of Review Treatment options for patients with acute lymphoblastic leukemia (ALL) beyond standard chemotherapy have grown significantly in recent years. In this review, we highlight new targeted therapies in ALL, with an emphasis on immunotherapy. Recent Findings Major advances include antibody-based therapies, such as naked monoclonal antibodies, antibody-drug conju- gates and bispecific T cell engaging (BiTE) antibodies, as well as adoptive cellular therapies such as chimeric antigen receptor (CAR) Tcells. Apart from the above immunotherapeutic approaches, other targeted therapies are being employed in Philadelphia chromosome-positive (Ph+) ALL, Philadelphia-like (Ph-like) ALL, and T cell ALL. Summary These new treatment strategies are changing the treatment landscape of ALL and challenging the current standard of care. Clinical trials will hopefully help determine how to best incorporate these novel therapies into existing treatment algorithms. . . . . . Keywords Acute lymphoblastic leukemia ALL Adult Treatment Immunotherapy Relapsed/refractory I. Introduction Significant advances in our understanding of ALL patho- genesis in recent years have led to the development of prom- Acute lymphoblastic leukemia (ALL) is a heterogeneous ising treatment options beyond conventional chemotherapy. group of hematologic malignancies characterized by impaired Many of these therapies target specific subsets of ALL, capi- differentiation and proliferation

Journal

Current Hematologic Malignancy Reports – Springer Journals

Published: Aug 4, 2018

There are no references for this article.